Therefore, the beneficial impact of FGF19 on glucose, lipid and bile acid homeostasis raise the possibility to pursue FGF19 as a therapeutic target for treating various metabolic disorders including diabetes, non-alcoholic fatty liver disease and cholestatic liver diseases [26, 27]. This evidence concerns the gene FGF19 and Cholestatic liver disease.